Licensing status

Publication and contact information

Endocrine/metabolic disease

Diabetic cardiomyopathy

Ceramide synthase 5

Studies in cell culture and in mice suggest antagonizing CERS5 could be useful for treating diabetic cardiomyopathy. In a mouse model of type 2 diabetes, overfeeding led to greater cardiac accumulation of myristate-bearing ceramides, autophagy and cardiac hypertrophy compared with those seen in healthy controls. In a cell culture assay of cardiac hypertrophy, CERS5 knockdown decreased cardiomyocyte hypertrophy, and CERS5 overexpression or treatment with myristate worsened cardiomyocyte hypertrophy, compared with vehicle or vector treatment. Next steps include characterizing the effect of Cers5 deletion on diabetic cardiomyopathy in mice.

SciBX 5(41); doi:10.1038/scibx.2012.1086
Published online Oct. 18, 2012

Unpatented; licensing status not applicable

Russo, S.B. et al. J. Clin. Invest.; published online Oct. 1, 2012;
Contact: L. Ashley Cowart, Medical University of South Carolina,
Charleston, S.C.